CBTN specimen will be used for reduced representation bisulfite sequencing - we will be profiling the transcriptome and epigenome. We will then compare these profiles between boys and girls with pediatric GBM to identify lesions that cause the difference in clinical outcomes of these patients.

The effective treatment of brain tumors requires a robust understanding of their biology. Using rare, high quality neurocytoma samples provided by the Children’s Brain Tumor Network, researchers seek to develop new treatments for this disease.

Newly developed technology is advancing the ability of researchers to gain important insight from small clinical specimens.

Changes to DNA that can give rise to cancers often create fusion proteins, proteins that may be useful as therapeutic targets. Using data from the Pediatric Brain Tumor Atlas, researchers will analyze for the presence of such proteins in an effort to advance treatment options for pediatric brain cancers.

Canine models have been considered useful in the study of human cancers and canine cancers, but more cross-comparative research is needed to optimize use of such models. Using data and specimens provided by the Children’s Brain Tumor Network, researchers seek to better understand the similarities and differences of canine and human tumors.

Understanding the origins of tumors, down to the originating tumor cell, could be imperative to the development of targeted therapies. Researchers will apply novel technologies to data from the Pediatric Brain Tumor Atlas in an effort to better understand the origin of many tumor types.

Adamantiomatious craniopharyngioma (ACP) is an intracranial tumor with no currently available targeted drug therapeutics. Using cell lines provided by the Children’s Brain Tumor Network, researchers will develop new models for use in identifying therapeutic opportunities for this disease.

Ependymoma is the third most common brain tumour of childhood, and current treatments are limited to surgery and radiation even in very young children. Both supratentorial and posterior fossa ependymoma are relatively chemotherapy resistant, and patients with relapsed or subtotally resected disease

Low grade gliomas are the most prevalent brain cancer among children and deeper study is needed to steer treatment protocol for patients that experience recurrence. Using samples provided by the Children’s Brain Tumor Network, researchers hope to better understand this disease and to identify new therapies.

Using cell lines provided by the Children’s Brain Tumor Network, researchers will attempt to build resources used to develop effective treatments and predict the treatment outcomes of pediatric brain tumor patients.

A lack of atypical teratoid rhabdoid tumor samples representing all subtypes has stalled the understanding of this complex disease. Identifying subtypes based on molecular characteristics may provide therapeutic strategies for suppressing growth, proliferation, and development of ATRT. Using cell lines provided by the Children’s Brain Tumor Network, researchers will investigate subtype-dependent responses to known treatments.

New targeted therapies are needed to address pediatric high grade gliomas with H3K27M mutations. The Children’s Brain Tumor Network will provide researchers with pHGG cell lines and data to pursue the development of therapeutics.

Medulloblastoma is the most common form of brain cancer, and many patients experience tumor progression/recurrence despite treatment. Using flash frozen samples provided by the Children’s Brain Tumor Network, researchers will try to better understand medulloblastoma recurrence.

RNA-binding proteins (RBP) may play critical roles in medulloblastoma development studying their roles will provide additional direct and indirect targets for the treatment of these tumors and beyond. Researchers will utilize cell lines provided by the Children’s Brain Tumor Network in an effort to identify new targets in the pediatric forms of these tumors.

Recent work points to the enzyme IDO1 as a high value target for the treatment of adult glioma. Researchers will analyze samples provided by the Children’s Brain Tumor Network to determine whether IDO1 could serve as a therapeutic target for pediatric brain tumors as well.

Medulloblastoma is a tumor with many subtypes and noninvasive diagnostic tools are needed to accelerate diagnosis. Using rare samples made available through the Children’s Brain Tumor Network, researchers will analyze the use of noninvasive methods for tumor classification.

Medulloblastoma is the most common pediatric brain tumor, and yet there is still much to be learned in order to effectively treat this disease. Researchers will utilize cerebrospinal fluid samples provided by the Children’s Brain Tumor Network in an effort to identify molecular markers that could lead to improved diagnostics, therapies and outcomes.

Brain tumors are rare and when combined with other nervous system tumors account for ~ 2% of all cancers; however, they are the second most common type of pediatric cancer and the leading cause of childhood cancer-related mortality. The etiology and molecular features of most pediatric brain tumors

Recent research has found that newly identified RNA molecules, circular RNAs, play a role in an increasing number of cancers. Using samples provided by the Children’s Brain Tumor Network, this project will generate the largest open-access dataset of circular RNAs in SHH medulloblastoma.

GD2 is a molecule expressed on the surface of tumors such as high grade glioma or medulloblastoma that could serve as a therapeutic target. Researchers will use plasma samples provided by the Children’s Brain Tumor Network to screen for the presence of GD2 in various brain tumors.

The use of an oncolytic virus refers to the use of a virus to stimulate immune response in a tumor. Researchers will utilize carefully catalogued samples provided by the Children’s Brain Tumor Network to further explore the use of oncolytic viruses in the treatment of pediatric brain cancers.

The invasive nature of brain tumors points to a need for minimally invasive diagnostic and prognostic strategies. Using samples provided by the Children’s Brain Tumor Network, researchers will assess the usefulness of liquid biopsies in the care of pediatric medulloblastoma.

Many pediatric brain tumors are unable to be removed in surgery, requiring the development of new effective therapies. Using RNA samples provided by CBTN, researchers are producing important characterization of the tumors and biomarker data to be used by researchers around the world in the pursuit of such new approaches.

Astrocytes, a subset of nervous system cells found in medulloblastoma, may support the growth and survival for a subset of medulloblastoma tumors. Using samples provided by the Children’s Brain Tumor Network, researchers will seek to validate previous results in hopes of advancing development of novel therapeutic options.

GPC2 is a molecule expressed on the surface of cells in medulloblastoma and neuroblastoma cells. Researchers will analyze specimens provided by the Children’s Brain Tumor Network in an effort to determine whether GPC2 could serve as an immunotherapeutic target for the treatment of such tumors.

Medulloblastoma is the most common pediatric brain tumor. Researchers will analyze genetic data provided through the Pediatric Brain Tumor Atlas to better understand medulloblastoma subgroups and the therapies needed to treat them.

Researchers hope to determine patterns of protein expression in glioma that could lead to advancements in the diagnostics and treatments to improve the care of pediatric patients.

There are many established subtypes of pediatric ependymoma and they may require different modes of treatment. Using samples and data provided by the Children’s Brain Tumor Atlas, researchers seek to better understand these differences in an effort to direct personalized care.

Ependymomas constitute nearly one third of the central nervous system neoplasms among children aged < 3 years1. The disease remains a significant therapeutic challenge, with a 5-year overall survival rate < 55 % among this age group2 and no available chemotherapy of proven efficacy. The breadth of t

Preclinical models are used to mimic conditions of the human body and allow researchers to perform drug screening before use on a patient. There is a lack of robust preclinical models for ependymoma, and using samples provided by CBTN researchers are seeking to close this gap.

Spinal ependymomas do not respond well to currently available treatment. Using newly developed methods and cell lines provided by the Children’s Brain Tumor Network, researchers seek to advance individualized care of this disease.

Research is needed in the development of targeted therapies and treatment protocols for patients with recurrent medulloblastoma. This project will work towards just that using access to extensive data from the Pediatric Brain Tumor Atlas.

Pediatric high grade astrocytomas are very difficult to treat and decades of clinical trials on adult tumors has failed to improve outcomes. Researchers will utilize cell lines provided by the Children’s Brain Tumor Network to explore newly discovered mutational drivers of this tumor type in an effort to develop pediatric centric therapies.

Diffuse intrinsic pontine gliomas (DIPG) and atypical teratoid rhabdoid tumors (ATRT) develop some tumor forms that are particularly resistant to therapies. To better understand these differences, researchers will analyze DIPG and ATRT samples provided by the Children’s Brain Tumor Network.

Histone mutations have been identified as drivers of some pediatric brain cancers. Researchers seek to understand the role of such mutations in the development of pediatric high grade gliomas through analysis of rare specimens provided by the Children’s Brain Tumor Network.

In many cases of pediatric brain tumors, inherited DNA mutations could be an underlying cause but research into the identification of such mutations is greatly needed to propel development of new therapies. Researchers will use the Pediatric Brain Tumor Atlas to complete comprehensive research into the identification of such mutations.

Pediatric high grade gliomas are particularly challenging to treat. This project will utilize rare samples provided by the Children’s Brain Tumor Network to explore pHGG response to cancer treatments.

It is crucial that the mutational drivers of pediatric high grade gliomas (pHGGs) are better understood if new therapies are to be developed. Using samples from the Children’s Brain Tumor Network, researchers seek to identify drivers of pHGG progression.

Oligodendroglioma is a rare brain cancer that has been hard to study due to a lack of available biospecimens. The Children’s Brain Tumor Network will provide researchers with the rare specimens necessary to generate deeper understanding of this malignant tumor.

Dysembryoplastic neuroepithelial tumors (DNET) genetic origins are little understood. Using samples from CBTN BioBank, researchers are conducting studies to help answer questions about their development to identify novel drug therapies.

High grade gliomas (HGG) and diffuse intrinsic pontine gliomas (DIPGS) are still poorly understood. Using samples provided by the Children’s Brain Tumor Network, researchers seek to better understand the genetics of these tumor types in the pursuit of effective therapies.

High grade gliomas can affect patients of all ages, and cross-age group analysis could lead to advancements in care for all populations. Using samples and data provided by the Children’s Brain Tumor Atlas, researchers supported by the NCI seek to improve outcomes for patients experiencing these tumors.

Pediatric tumors have unique properties compared to adult tumors, requiring different treatment strategies for the same tumor type. Using samples provided by the Children’s Brain Tumor Network, researchers will carry out comprehensive comparisons of pediatric meningioma and schwannoma to map these critical areas to develop novel treatments.

In order to make therapeutic advancements, comprehensive research must be conducted to molecularly understand tumors. The Center for Pediatric Tumor Cell Atlas project, part of the Human Tumor Atlas Network of the NIH Cancer Moonshot initiative will utilize rare samples provided by the Children’s Brain Tumor Network to better understand pediatric high grade gliomas and neuroblastomas.

Understanding the similarities and differences across subtypes of glioma is necessary to provide targeted care. Researchers will utilize data from the Pediatric Brain Tumor Atlas in an effort to more accurately categorize and treat pediatric high grade gliomas.

Preliminary analysis of data on the immune response of pediatric low grade glioma shows promising leads for treatment prioritization. Using data from the Pediatric Brain Tumor Atlas, researchers will deepen this analysis on a larger dataset.

The recently characterized molecular marker, histone H3 K27M, could prove important to the treatment of pediatric gliomas. Researchers will interrogate data from the Pediatric Brain Tumor Atlas in order to better understand this new class of malignant gliomas.

Starting with gliomas with H2K27M mutations, researchers are investigating genes related to the immune system and their possible role in future immune system-based treatments. Using the Pediatric Brain Tumor Atlas, researchers are comparing the genetics of various tumor types and mutations.

Comprehensive research into high grade gliomas is necessary to find new effective therapies. Using the Pediatric Brain Tumor Atlas, researchers will identify patterns in gene expression that could pave the way for the development of new therapeutics.

Research into adult glioblastoma has revealed a relationship between heightened levels of enzymes that suppress the immune system and a lowered survival rate. Researchers are using the Pediatric Brain Tumor Atlas to explore this relationship in pediatric high-grade pediatric brain cancer.

Comprehensive information on the genetics of pediatric gliomas is necessary in the search for effective diagnostic and prognostic tests, targets and treatments. Researchers will apply recently developed algorithms, used by computers to analyze data, to information from the Pediatric Brain Tumor Atlas in hopes of developing novel tests and therapies.

Immunotherapy is a promising form of therapy for high grade tumors, but more comprehensive research is needed. Through accessing the Pediatric Brain Tumor Atlas, researchers will produce data that could lead to the development of patient-specific treatments.

The development of treatment for Gliomatosis cerebri and other high grade gliomas relies on a comprehensive understanding of each tumor type. Using the Pediatric Brain Tumor Atlas alongside other open access datasets, researchers will map and analyze how tumors change over time, across locations, and the specific proteins created in Gliomatosis cerebri.

Integrative research is needed to advance the treatment options for pediatric cancers. Researchers will analyze data provided through the Pediatric Brain Tumor Atlas in an effort to identify new opportunities in the treatment of pediatric cancers.

Information regarding the mutations of genes in pediatric brain tumors is integral in developing new diagnostics and treatments. Researchers will use the Pediatric Brain Tumor Atlas to analyze comprehensive genetic information across pediatric brain tumor types, which will be used by researchers in the development of new treatments.

Gene fusions and fusion proteins may serve as targetable cancer drives. Through analysis of data from the Pediatric Brain Tumor Atlas, researchers seek to accelerate the development of therapies for pediatric brain cancers.

Understanding the mutations that occur in both neurofibromatosis 1 patients and brain tumors could provide a deeper understanding of how both tumor types form. Using data provided by the Pediatric Brain Tumor Atlas, researchers will identify genes that are mutated in both tumor types.

Ependymomas are a common form of growth in pediatric brain cancer patients, but there is a lack of effective treatment options currently available. Using the Pediatric Brain Tumor Atlas researchers will gain a greater understanding of ependymoma growth, helping to guide therapeutic opportunities.

Differences in the genetics of same-type tumors can lead to different outcomes for patients, including impacts on the neurological functioning of pediatric cancer survivors. Using the Pediatric Brain Tumor Atlas and individual patient assessments, researchers seek to better understand the effects of such genetic differences and to use that information to inform clinical care decisions.

Researchers are building an open access resource to improve treatments of pediatric cancers. These researchers will incorporate the Pediatric Brain Tumor Atlas, adding invaluable information about pediatric cancers and gene expression.

Comprehensively sequencing the DNA found in tumor samples is crucial for the development of new treatments. Researchers will compare their targeted DNA sequencing strategies with Whole Genome Sequencing data from the Pediatric Brain Tumor Atlas in hopes of developing improved cancer diagnostics.

Mixed Neuronal-Glial Tumors (MNGT) are a benign category of tumor associated with seizures. Using the Pediatric Brain Tumor Atlas, researchers will analyze MNGT in hopes of guiding the development of treatments and predictive assessments.

Pediatric brain tumors are the leading cause of disease related death in children. Major factors contributing to treatment failures for children with brain tumors include: i) the lack of comprehensive molecular description of the disease and an associated dearth of integration of the tumors’ biologi

The study of a tumor’s immune repertoire includes an analysis of T cell receptors and B cell receptors that allow an immune system to adapt to changes and launch an immune system response. Using the Pediatric Brain Tumor Atlas, researchers will study the immune repertoire across tumor types which could lead to new immunotherapies.

Immunotherapy is a treatment strategy for patients that utilizes their own immune system to attack and remove cancer, and more research is needed to utilize such therapies for the treatment of pediatric brain cancers. Researchers will screen data provided by the Pediatric Brain Tumor Atlas in an effort to identify possible immunotherapy targets.

Genetic alterations play a role in the growth and persistence of pediatric brain tumors. Using the Pediatric Brain Tumor Atlas, researchers will explore genetic alterations across cancer types in a pursuit of new therapies.

Embryonal tumors with multilayer rosettes (ETMR) have recently been reclassified and clinical investigations are needed to understand their occurrence and prevalence. ETMR specimens from the Pediatric Brain Tumor Atlas will be used by researchers to begin building a robust understanding and characterization of the tumor.

Pediatric meningiomas are extremely rare tumors and are often of an aggressive form unresponsive to available treatments. Specimens from the Pediatric Brain Tumor Atlas will allow researchers to study this rare tumor in an effort to develop targeted therapies.

Genetic tests for pediatric patients born with medical conditions currently have a low rate of diagnosis and Mendelian disorders are often missed in analysis. Using the Pediatric Brain Tumor Atlas, researchers will develop algorithms to more accurately diagnose Mendelian disorders in pediatric brain cancer patients to improve outcomes for patients.

Radiation injury can occur in pediatric brain cancer patients undergoing radiation therapy. Using data from the Pediatric Brain Tumor Atlas, researchers hope to identify genetic features that may contribute to risks for receiving radiation therapy.

Understanding mutations found in the DNA of mitochondria could lead to the development of targeted cancer therapies. Using the Pediatric Brain Tumor Atlas, researchers will analyze mitochondrial mutations across pediatric brain cancer types to better understand their development.

There is a great need to find new targets for pediatric brain cancer therapeutics, requiring comprehensive analysis of tumor types. Access to the unique dataset available through the Pediatric Brain Tumor Atlas and computational support from CBTN will allow researchers to carry out this research.

Data points to disparities of cancer diagnosis and outcomes across children in different racial and ethnic groups. In an effort to better understand these disparities, researchers will interrogate data provided by the Pediatric Brain Tumor Atlas.

Ependymoma is an aggressive disease in children and currently available therapies are insufficient in treatment. Using ependymoma cell lines provided by CBTN, researchers seek to validate recent studies that may guide emerging therapies.

Medulloblastoma is hard to treat, and recent work points to a specific family of proteins that could serve as suppressors for this tumor. Researchers will use data and samples provided by the Children’s Brain Tumor Network in an effort to find ways to exploit these proteins for new therapies.

The therapy resistance of supratentorial and posterior fossa ependymoma points to the need for new treatment options. The Children’s Brain Tumor Network will provide the samples needed to explore therapeutic vulnerabilities of these tumor types.

Primary resistance to chemotherapy is a major challenge in treating brain tumors today. Finding novel and specific tumor dependencies is therefore essential for effective drug development and improving patient outcomes.High-grade gliomas (HGG) are the most aggressive brain tumors in children and you

Research is greatly needed to expand understanding of oligodendroglioma biology. The Children’s Brain Tumor Network will be providing rare samples necessary to better understand this tumor and to explore new treatment options.

The blood brain barrier (BBB) is known to limit the effectiveness of glioblastoma treatments. Using samples provided by the Children’s Brain Tumor Network, researchers seek to enhance understanding of the BBB environment and of therapeutics that can pass the BBB.

Pediatric low grade gliomas require further research to better understand differences in tumor aggressiveness. Using tissue and blood cell samples provided by the Children’s Brain Tumor Network, researchers will explore those differences in the pursuit of therapeutic vulnerabilities.

Brain tumors are rare and when combined with other nervous system tumors account for ~ 2% of all cancers; however, they are the second most common type of pediatric cancer and the leading cause of childhood cancer-related mortality. The etiology and molecular features of most pediatric brain tumors

A robust resource on the drug response across pediatric cancer types will be helpful to guide clinical decisions. Using samples provided by the Children’s Brain Tumor Network, researchers will create and share this important data resource.

Choroid plexus tumors, including choroid plexus carcinoma, are rare tumors with limited treatment options. Researchers will use tissue provided by the Children’s Brain Tumor Network to establish cell lines that will be used to propel research into CPT treatment forward.

Medulloblastoma relapse is unfortunately common and leaves patients with a poor prognosis. Researchers will use tumor samples and data provided by the Children’s Brain Tumor Network to better understand medulloblastoma relapse, how tumors evolve, and the mechanisms of metastasis in an effort to design effective therapeutic strategies.

We have previously reported a high frequency of AKT activation, a downstream target of PTEN, in pediatric high-grade gliomas (pHGGs), as assessed by immunohistochemistry (IHC), and demonstrated that this was associated with an adverse prognosis. Compared to adult high-grade gliomas, pHGGs show a low

Recent studies have reclassified thalamic tumors in the category of midline gliomas and more research is needed to develop accurate diagnostics and effective treatments for this tumor type.

Research into adult cancer has benefited greatly from large scale genomic research. Until now due to the limited resources and availability pediatric brain tumors have not been part of large-scale genomic generation efforts. The CBTN aims to create a comprehensive genomic atlas for use by researchers worldwide to unlock how brain tumors develop, grow, survive, and how they can be treated and cured.

There are many molecules associated with cell division that could serve as targets for cancer therapy. Researchers will analyze specimens provided by the Children’s Brain Tumor Network to determine whether drugs that inhibit such molecules could increase radiation sensitivity in pediatric brain cancer patients and improve outcomes.

Low grade gliomas are often associated with the genetic disorder neurofibromatosis type 1 and research is needed to develop targeted therapies for such tumors. The Children’s Brain Tumor Network is providing researchers with rare samples necessary to accelerate progress in the treatment of NF1-LGGs.

A greater understanding of the abundance of telomeres and their relationship to the growth of high grade gliomas (HGG) could lead to new therapies. Using the Pediatric Brain Tumor Atlas, this study seeks to build this knowledge for use by researchers around the world.

Studies have shown that many patients with germline mutations, mutations that can be passed down, have a predisposition to central nervous system tumors. Researchers will use data from the Pediatric Brain Tumor Atlas along with patient’s clinical data and family history to study the impacts of predisposition on patient outcomes.

Transcription factors are proteins that control the rate of transcription, the process by which information from DNA is copied into a new molecule of RNA. Transcription factor FoxM1 has been found to play a role in the growth of glioblastoma and researchers seek to better understand this connection in the pursuit of targeted therapies.

Certain subtypes of ependymoma are associated with poor outcomes as with diffuse intrinsic pontine glioma (DIPG) brain tumors. Comprehensive research into their genetics using the Pediatric Brain Tumor Atlas is being carried out by researchers in an effort to develop treatments with better outcomes.

Pediatric meningiomas are extremely rare tumors and although the mechanisms involved in one form, NF2, are well described, research into even rarer mutations is greatly needed. Specimens from the Pediatric Brain Tumor Atlas will allow researchers to study this rare tumor in an effort to develop targeted therapies for patients with YAP1 fusion meningiomas.

Pediatric diffuse astrocytomas are particularly hard to remove in surgery and more treatment options for patients with this type of tumor are greatly needed. Researchers will use the Pediatric Brain Tumor Atlas to conduct comparisons of tumors across age groups to further define the characteristics of this tumor type and develop more targeted therapies for pediatric brain cancer patients.

Tumor classification and segmentation are important steps in characterizing tumors to develop treatment for cancers, and researchers have begun developing algorithms that could streamline the classification process. Researchers will use data from the Pediatric Brain Tumor Atlas to expand the analysis of newly developed algorithms to the pediatric brain cancer population.

Structural variants (SVs) are mutations that involve large segments of DNA and are associated with mechanisms of cancer development and growth. Researchers will access the Pediatric Brain Tumor Atlas in an effort to better understand the formation of SVs across tumor types and their effect on pediatric brain cancer progression.

The origin and fatality of diffuse intrinsic pontine gliomas (DIPG) may be connected to mutations in the proteins that hold DNA together. Using the Pediatric Brain Tumor Atlas, researchers are deepening their understanding of this connection.

Alternative splicing plays a critical role in the function of a cell and understanding this process could lead to new therapies for pediatric brain cancer patients. Using the Pediatric Brain Tumor Atlas, researchers seek to identify and understand alternative splicing’s role in the development of brain tumors.

Previous research into choroid plexus tumors (CPT) has shown there to be distinct subtypes, but the drivers of these subtypes and therefore the targeted therapies needed to treat them are unknown. Data from rare, high quality specimens catalogued in the Pediatric Brain Tumor Atlas will be utilized to complete this analysis.

Diffuse intrinsic pontine glioma (DIPG) is an aggressive type of pediatric brain cancer associated with poor outcomes. Researchers will use data from the Pediatric Brain Tumor Atlas in the pursuit of new therapies for patients with DIPG.

Genomic data, tumor imagery, and text-based data are all important in the diagnosis and treatment of cancers. Through computational comparisons of these data types made available through the Pediatric Brain Tumor Atlas, researchers seek to improve the accuracy of cancer diagnostics.

Preclinical models are a common way for researchers to study tumor types as well as test diagnostics and therapies. Researchers seek to validate their preclinical models for malignant pediatric tumors through comparison to patient-derived tumor data housed in the Pediatric Brain Tumor Atlas.

Studies have shown a link between microsatellites, repeating units of DNA, and the development of several cancer types. Researchers will access the Pediatric Brain Tumor Atlas in an effort to identify the location of microsatellites and deepen the understanding of their connection to cancer development across brain tumor types.

Anaplastic pleomorphic xanthoastrocytomas (PXAs) are a rare and deadly pediatric brain cancer. Using data from the Pediatric Brain Tumor Atlas, researchers will perform detailed analysis on PXA samples in a pursuit of new therapies.

RASopathies are a group of rare genetic conditions sometimes associated with central nervous system cancers development and growth, but researchers believe their connection could be more common than previously thought. This project seeks to understand this connection through analysis of the Pediatric Brain Tumor Atlas.

Individuals who have undergone treatment for craniopharyngiomas in childhood experience lasting life-altering issues including hypothalamic obesity. Through access to the data available through the Pediatric Brain Tumor Atlas, researchers will examine risk factors in an effort to better prevent and treat hypothalamic obesity.

Many pediatric brain cancer patients experience toxicities related to the use of vincristine in treatment protocols. Using the Pediatric Brain Tumor Atlas, this study will help to define the frequency of genetic risks for side effects in an effort to lessen the need for treatment reductions.

Tumor classification through imaging is an important part of pediatric cancer diagnosis and treatment. Researchers will investigate tumor imagery and genomic data provided by the Children’s Brain Tumor Network in an effort to advance the accuracy of tumor classification.

Understanding the incidence and classification of T cell receptors of pediatric brain tumors is necessary to develop new therapies. Using data from the Pediatric Brain Tumor Atlas, researchers seek to better understand the tumor cellular immune system.

Epithelial-to-mesenchymal transition (EMT) derived stem cells and cancer cells share certain common characteristics. Using data from the Pediatric Brain Tumor Atlas, researchers will perform a variety of comprehensive analyses in an effort to better understand the link between the EMT and cancer growth.

Tumor-associated macrophages (TAMs) represent possible targets in the treatment of pediatric brain cancers. Researchers will analyze data from the Pediatric Brain Tumor Atlas in an effort to identify such targets.

Understanding rare gene fusions in tumors provides therapeutic leads in the treatment of pediatric brain cancer. Access to the Pediatric Brain Tumor Atlas will give researchers the genetic data necessary to pursue this research.

Somatic structural variants (SSVs) are mutations arising in tumors that involve large segments of DNA. Using data from the Pediatric Brain Tumor Atlas, researchers will identify SSV patterns in pediatric cancer types that could lead to new therapies.

This project aims at identifying variants in the CBTN germline DNA whole genome sequencing data that are reported and/or found in other diseases, esp. birth defects and rare Mendelian disorders, hoping to explain/reveal shared genetics between pediatric cancer and rare diseases.

Cerebral cavernous malformations (CCMs) can be inherited and can also form sporadically. Researchers will interrogate data provided by the Pediatric Brain Tumor Atlas in an effort to understand how both forms are related.

A gene capable of moving within a genome, PGBD5, has been previously examined for its role in the development of brain cancers. Researchers will leverage data available through the Pediatric Brain Tumor Atlas to expand on this work in a pursuit of therapies for pediatric brain cancers.

Research has revealed that histopathological analysis alone does not provide enough information about tumor subtypes and more precise diagnostics are needed to guide treatment decisions. Researchers will analyze tumor imagery alongside comprehensive genetic data in an effort to develop more accurate brain tumor diagnostics.

The treatment of rare and deadly pediatric brain cancer requires an international effort to increase the impact of new discoveries. Through incorporation of data from the Pediatric Brain Tumor Atlas, researchers seek to develop the Australian Bioinformatics Commons, the largest data sharing initiative ever undertaken in Australia.

Precision oncology can be a challenge for pediatric brain tumors. Researchers will interrogate data from the Pediatric Brain Tumor Atlas in an effort to explain poor outcomes and guide treatments for patients with under-explored mutations.

DNA damage susceptibility in adults has been found to be strongly associated with future cancer diagnosis, could the same be true for pediatric patients? Researchers will investigate data from the Pediatric Brain Tumor Atlas using newly developed algorithms in an effort to answer that question.

Children with high grade brain cancers experience a low likelihood of survival from current treatments and often experience toxicity from their treatments as well. Through interrogation of the Pediatric Brain Tumor Atlas, researchers will search for biomarker targets that will be used in the development of new therapies.

Targeted therapeutic options are limited for patients with diffuse intrinsic pontine glioma (DIPG). Researchers will perform state of the art analysis on data from the Pediatric Brain Tumor Atlas in an effort to identify new therapies for patients with DIPG.

Neoantigens are targets that can be utilized by immunotherapy, a form of therapy that uses a patient’s own immune system to attack a tumor. Researchers will carry out research to identify neoantigens using data provided through the Pediatric Brain Tumor Atlas.

This project will investigate the role of mutations in mitochondrial DNA with brain cancer progression/aggressiveness.

Medical imagery is an important part of cancer diagnostics and treatment. Researchers will use medical imagery available through the Pediatric Brain Tumor Atlas to evaluate new anomaly detection methods in an effort to advance individualized cancer diagnostics.

Ependymoma is a pediatric brain tumor with many subtypes, each requiring different treatment protocols. Through interrogation of the Pediatric Brain Tumor Atlas, researchers are looking for drivers in ependymoma subtypes that could guide the development of targeted therapies.

Recent research has identified mutations that drive the development of adult cancers, opening the door for new therapies. Researchers will be using data from the Pediatric Brain Tumor Atlas to investigate such drivers as they apply to pediatric brain cancers.

Chordoma is a spinal bone tumor with limited successful therapeutic options. Researchers will interrogate chordoma data from the Pediatric Brain Tumor Atlas in an effort to improve therapies.

Comprehensive, integrative research is needed to advance the diagnosis and care of patients with high grade glioma (HGG). Using data provided through the Pediatric Brain Tumor Atlas, researchers will search for potential drug targets for the treatment of HGGs.

Preclinical models are a common method used to study the progression of tumors and their responses to treatment options. Researchers propose to use data from the Pediatric Brain Tumor Atlas to perform cross-species comparisons in an effort to develop more accurate models.

Understanding tumor genesis, or the origin of a tumor, involves building a neurodevelopmental map, cell by cell. Researchers will use data from the Pediatric Brain Tumor Atlas to build a map to better understand and determine the cell of origin for a range of CNS tumors, paving the way for targeted therapies.

Many pediatric brain cancers are associated with the major histocompatibility complex (MHC). Researchers will use data from the Pediatric Brain Tumor Atlas to investigate the role of these genes in pursuit of advanced treatments for patients with MHC-related brain cancers.

Tumor classification can be challenging, but it is necessary in order to make the most impactful treatment decisions for patients. Researchers will integrate data from the Pediatric Brain Tumor Atlas in an effort to strengthen tumor classification for pediatric brain cancers.

The treatment of pediatric brain tumors varies depending on tumor type and tumor subtypes, such as tumors with BCOR mutation. Researchers will conduct a retrospective analysis of patients with BCOR tumors using data from the Pediatric Brain Tumor Atlas in an effort to better understand this subtype and clinical outcomes.

The tumor microenvironment includes the variety of molecules and cells found within a tumor mass. Researchers are examining data provided through the Pediatric Brain Tumor Atlas in an effort to identify therapeutic targets for many forms of pediatric brain cancer.

Researchers hypothesize that the identification of transposition events in high grade gliomas could open therapeutic leads. Using data from the Pediatric Brain Tumor Atlas, researchers will pursue new insight into the effect of transposition events in the origin and growth of pediatric tumors.

Human development, disease risk, and response to treatments are often different in males and females. Researchers will interrogate data available through the Pediatric Brain Tumor Atlas to determine whether cancer treatments could be optimized based on such differences.

The identification of germline protein expression in brain cancer cells is pivotal in guiding the development of new treatments.s. Using the Pediatric Brain Tumor Atlas, researchers seek to create an important resource on the details of protein expression across many individual brain cancer types.

Artificial Intelligence (AI) has applications across many fields. Researchers are working to apply AI-based techniques in the detection and treatment of pediatric brain cancers through access to the Pediatric Brain Tumor Atlas.

There are many cases of intracranial germ cell tumors that can not be explained through currently identified cancer mechanisms. Researchers will use newly developed computational tools to interrogate data from the Pediatric Brain Tumor Atlas in an effort to shed new light on this dangerous pediatric brain cancer.

One form of therapy that is promising for high grade glioma patients is CAR T cell therapy. Researchers will analyze data from the Pediatric Brain Tumor Atlas to inform novel targets for this promising therapy.

Dogs have been considered useful models in the study of human cancers and cancers that occur in canines. Researchers will expand their cross-species comparative cancer study with data provided through the Pediatric Brain Tumor Atlas.

Master regulator proteins drive cancer growth and understanding the role they play in patients with DIPG could unlock opportunities for novel treatments. Researchers will analyze DIPG data from the Pediatric Brain Tumor Atlas in order to evaluate new treatment options.

Ion channels, special cellular proteins, could serve as new targets for the treatment of diffuse intrinsic pontine gliomas. Researchers will try and identify DIPG associated ion channels through interrogation of data from the Pediatric Brain Tumor Atlas.

Senescence refers to a cell that is in a stage where they do not divide, and researchers believe senescence could have a roll in the different behaviors of glioma in pediatric patients vs. adult patients. Using rare specimens from infants and children provided by the Children’s Brain Tumor Network, researchers will analyze senescence in glioma tissues in comparison to adult cancers.

The blood brain barrier is an issue clinicians face when trying to deliver drugs for the treatment of brain cancers. Using rare samples and imaging data provided by the Children’s Brain Tumor Atlas, researchers will investigate new avenues for drug delivery.

Gliomas are the most common central nervous system (CNS) tumors in children and adolescents, and they display a particularly broad range of clinical behavior. The impact of CNS tumors on infant mortality is very important. During the last decades there have been no advances in the prognosis of these

Recent work has pointed to dysregulation of a cellular process called the mesenchymal-epithelial transition (MET) as a driver for diffuse midline gliomas (DMGs). This project will further explore this dysregulation in an effort to identify new therapeutic targets for DMGs.

Novel approaches are needed in the treatment of pediatric high grade gliomas. Using cell lines provided by the Children’s Brain Tumor Network, researchers will identify novel therapeutic targets.

Research is needed to better understand the underlying cause of diffuse midline gliomas (DMGs). Using data provided by the Children’s Brain Tumor Atlas, researchers on this project will investigate mutations affecting histones in DMGs.

Analyze the relationship between the expression of specific genes and the prognosis in pediatric gliomas. Discover possible upstream or downstream genes. Find crucial genes which can be used in clinical treatment.

A comprehensive approach is needed to advance the understanding and clinical care options for patients with diffuse midline gliomas (DMGs). Using DMG samples provided by the Children’s Brain Tumor Network, researchers seek to identify avenues for new therapies.

Glioma is responsible for more childhood deaths and the greatest number of years of potential life lost than any other type of cancer. Despite advances in surgery, radiation and chemotherapy, pediatric supratentorial high grade gliomas (pHGG) including anaplastic astrocytoma and glioblastoma (GBM) are among the most aggressive of these tumors and confer a 2 year survival rate of only ~10-30%. On the contrary, pediatric supratentorial low grade gliomas (pLGG) require less aggressive therapy and are less likely to recur though can be very debilitating with high morbidity. It is imperative that we discover how best to use new therapies for these devastating diseases.

Pediatric high-grade gliomas (pHGGs) is a deadly disease and research is needed to aid in the development of new therapies. Researchers will use preclinical models provided by the Children’s Brain Tumor Network in an effort to identify possible targets for the treatment of pHGGs.

Intracranial ependymomas are a common pediatric brain cancer with many subgroups that may respond differently to different therapies. Using cell lines provided by the Children’s Brain Tumor Network, researchers seek to better understand these differences in an effort to advance positive patient outcomes.

Oncogenic fusions involving receptor tyrosine kinases (RTK) provide an excellent opportunity for therapeutic targeting but the clinical and molecular landscape of pediatric RTK-driven gliomas remains largely uncharted. To define clinically-relevant tumor subgroups and assess their prognostic significance, we will evaluate the correlation between molecular and clinical characteristics. This project will provide mechanistic insights into RTK-fused gliomas and enable precision medicine approaches to treat these tumors.

Correlating the genomic and epigenomic features of pediatric meningiomas with biological behavior

This study will utilize artificial intelligence algorithms to predict underlying mutational status and outcomes for pediatric low grade glioma based on complex brain tumor MRI imaging features.